They do not reliably increase employment, but they do kick people off essential benefits like food assistance and healthcare,” said an expert at the Economic Policy Institute. After nominees for U.S.
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high costs—often exceeding $1,000 per month—put them out of reach for many ...
These ranges are different than they are in the rest of the country because of the high cost of living in Alaska. But if you qualify for Medicaid, you can't get subsidies. You can use a subsidy to ...
Conduent has been a trusted partner to HCS since 2007 when it was first selected to deliver Medicaid Enterprise Systems technology solutions to the state of Alaska. The company will continue to ...